tiprankstipranks
Trending News
More News >
Kenvue, Inc. (KVUE)
NYSE:KVUE
US Market
Advertisement

Kenvue, Inc. (KVUE) AI Stock Analysis

Compare
926 Followers

Top Page

KV

Kenvue, Inc.

(NYSE:KVUE)

Rating:68Neutral
Price Target:
$24.00
â–²(9.09%Upside)
Kenvue's overall stock score reflects a solid financial foundation with strong margins and cash flow. However, technical indicators and high valuation present near-term challenges. The company's strategic execution and market share gains offer potential for future growth, despite current headwinds in certain segments.
Positive Factors
Leadership Change
The appointment of Mr. Kirk Perry as interim CEO indicates a commitment to conducting a comprehensive search for the company’s next permanent CEO, following the replacement of both the CEO and CFO.
Portfolio Optimization
Review of strategic alternatives announced by KVUE could lead to portfolio simplification, which may enhance operating performance to accelerate profitable growth.
Strategic Review
The announced CEO transition and review of strategic alternatives should be well received, given mostly disappointing results and a number of execution challenges since the company’s IPO in 2023.
Negative Factors
Financial Performance
Preliminary 2Q25 results indicating OSG -4.2% suggest that patience has worn out due to disappointing performance.
Sales Performance
Preliminary Q2 sales and earnings results were below expectations, with organic sales at -4.2% compared to the Street’s -1% prior.
Skin Health & Beauty Segment
The skin health & beauty segment shows signs of weakness, with weak volumes likely to persist due to soft sales in sun care and greater pricing investments.

Kenvue, Inc. (KVUE) vs. SPDR S&P 500 ETF (SPY)

Kenvue, Inc. Business Overview & Revenue Model

Company DescriptionKenvue, Inc. (KVUE) is a prominent player in the consumer health industry, specializing in the development, production, and marketing of a diverse range of health and wellness products. The company operates across several sectors, including over-the-counter medications, skincare, and other personal care products. Kenvue is committed to enhancing consumer health by providing innovative and reliable solutions that cater to the evolving needs of its global customer base.
How the Company Makes MoneyKenvue, Inc. generates revenue primarily through the sale of its health and wellness products across various segments, including over-the-counter medications, skincare, and personal care. The company's revenue streams are largely driven by its extensive portfolio of trusted brands, which are distributed through a wide network of retail partners, pharmacies, and online platforms. Kenvue benefits from strategic partnerships and collaborations that enhance its market reach and product offerings. Additionally, the company's focus on research and development enables it to introduce new and innovative products, thus expanding its revenue potential. Key factors contributing to Kenvue's earnings include strong brand recognition, a diverse product lineup, and a robust distribution network.

Kenvue, Inc. Earnings Call Summary

Earnings Call Date:Jul 14, 2025
(Q1-2025)
|
% Change Since: 3.09%|
Next Earnings Date:Oct 23, 2025
Earnings Call Sentiment Neutral
The earnings call presented a mixed outlook for Kenvue, with strong execution of strategic plans and market share gains in certain segments overshadowed by organic sales declines and challenges in the Skin Health and Beauty segment. The impact of tariffs and foreign exchange rates also posed significant challenges.
Q1-2025 Updates
Positive Updates
Strong Execution of Strategic Plans
Kenvue demonstrated strong execution of strategic plans, maintaining organic sales growth outlook for the year amidst significant macro shifts and seasonal variability.
Tylenol Outperforms in the US Market
Tylenol gained share for the eleventh straight quarter, surpassing competitors, driven by successful innovation and consumer engagement campaigns, such as the 'Greatness Hurts' football themed campaign.
Zyrtec Gains Market Share
Zyrtec improved both value and volume share, increasing household penetration and distribution in the Allergy segment.
Completion of Transition Services Agreement Program
Kenvue completed the Transition Services Agreement program, streamlining operations and exiting over 2,300 TSAs without business disruption.
Aveeno’s Double-Digit Growth in EMEA
Aveeno brand experienced double-digit growth in EMEA, particularly in the UK and Central Europe, contributing to the twelfth consecutive quarter of organic sales growth in the region.
Negative Updates
Organic Sales Decline
Organic sales declined 1.2% compared to Q1 last year, with a significant 3% to 4% headwind from destocking in China and strategic investments in pricing and trade in the US.
Skin Health and Beauty Segment Challenges
Organic sales in the Skin Health and Beauty segment declined by 4.8% due to destocking in China, a soft sun season in Latin America, and strategic price investments in the US.
Impact of Tariffs and Foreign Exchange Rates
Adjusted operating margin and adjusted diluted EPS outlooks were updated to reflect incremental costs associated with current tariffs and foreign exchange rates.
Essential Health Segment Performance
The Essential Health segment saw flat organic sales as growth in Wound Care was offset by declines in Women's Health and Oral Care, impacted by competitive pressures and destocking in Asia.
Company Guidance
During the Kenvue First Quarter 2025 Earnings Conference Call, the company provided key guidance metrics for the year. Despite a 1.2% decline in organic sales in Q1, Kenvue maintained its full-year organic sales growth outlook of 2% to 4%, anticipating a growth acceleration in the second half. Adjusted operating margin is expected to contract slightly due to $150 million in estimated tariff impacts, though Kenvue is implementing mitigation strategies through productivity initiatives and supply chain optimization. Adjusted diluted EPS is projected to be flat for 2025, with a low-single-digit increase on a constant currency basis. The company highlighted strong execution in its Self Care segment, with organic sales growth of 0.3%, while Skin Health and Beauty saw a 4.8% decline due to destocking and strategic price investments. Looking forward, Kenvue plans to leverage innovation and marketing to improve its competitive position amidst dynamic market conditions.

Kenvue, Inc. Financial Statement Overview

Summary
Kenvue, Inc. demonstrates sound financial health, characterized by strong margins and cash flow. While there is a slight contraction in revenue growth, the company exhibits efficient operational management and a balanced capital structure.
Income Statement
78
Positive
Kenvue, Inc. shows a steady revenue base with a Gross Profit Margin of approximately 58% TTM, aligning well with industry standards. However, the Revenue Growth Rate TTM is slightly negative at -0.99%, indicating a minor contraction in sales. The Net Profit Margin TTM stands at 6.9%, which is reasonable, though there is room for improvement. EBIT and EBITDA margins are robust at 15.8% and 20% respectively, indicating efficient operational management.
Balance Sheet
75
Positive
The company maintains a healthy Debt-to-Equity ratio of 0.87, suggesting moderate leverage. Return on Equity TTM is 10.5%, indicating decent profitability relative to shareholder equity. The Equity Ratio is 38.3%, reflecting a stable capital structure. However, the gradual decline in Stockholders' Equity over the past periods warrants attention.
Cash Flow
82
Very Positive
Cash flows are strong, with a Free Cash Flow to Net Income ratio of 1.37, indicating solid cash generation relative to earnings. Operating Cash Flow to Net Income ratio is 1.81, suggesting strong operational cash flow management. The Free Cash Flow Growth Rate of 8.63% TTM shows positive momentum in cash generation capabilities.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue15.30B15.46B15.44B14.95B15.05B14.47B
Gross Profit8.88B8.96B8.64B8.29B8.42B7.85B
EBITDA3.06B2.47B3.17B3.64B3.87B3.79B
Net Income1.06B1.03B1.66B2.06B2.08B-879.00M
Balance Sheet
Total Assets26.26B25.60B27.85B27.32B27.93B29.18B
Cash, Cash Equivalents and Short-Term Investments1.06B1.07B1.38B1.23B740.00M618.00M
Total Debt8.74B8.72B8.43B116.00M258.00M320.00M
Total Liabilities16.20B15.93B16.64B7.29B7.53B10.82B
Stockholders Equity10.05B9.67B11.21B20.02B20.40B18.36B
Cash Flow
Free Cash Flow1.45B1.33B2.70B2.15B39.00M3.17B
Operating Cash Flow1.91B1.77B3.17B2.52B334.00M3.40B
Investing Cash Flow-440.00M-425.00M-488.00M-390.00M-171.00M-83.00M
Financing Cash Flow-1.55B-1.56B-2.53B-1.58B0.00-3.46B

Kenvue, Inc. Technical Analysis

Technical Analysis Sentiment
Positive
Last Price22.00
Price Trends
50DMA
22.24
Negative
100DMA
22.60
Negative
200DMA
22.17
Negative
Market Momentum
MACD
-0.07
Negative
RSI
57.30
Neutral
STOCH
67.30
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KVUE, the sentiment is Positive. The current price of 22 is above the 20-day moving average (MA) of 21.22, below the 50-day MA of 22.24, and below the 200-day MA of 22.17, indicating a neutral trend. The MACD of -0.07 indicates Negative momentum. The RSI at 57.30 is Neutral, neither overbought nor oversold. The STOCH value of 67.30 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for KVUE.

Kenvue, Inc. Risk Analysis

Kenvue, Inc. disclosed 59 risk factors in its most recent earnings report. Kenvue, Inc. reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 3 New Risks
1.
We have debt obligations that could adversely affect us. Q4, 2024
2.
We may not fully realize the expected cost savings and/or operating efficiencies associated with our restructuring programs, including the 2024 Multi-Year Restructuring Initiative, or our strategic initiatives, which could adversely affect us. Q4, 2024
3.
Uncertainty in the development, deployment, use and regulation of artificial intelligence in our internal processes, manufacturing operations, products and services, as well as our business more broadly, could adversely affect us. Q4, 2024

Kenvue, Inc. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (65)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
ULUL
71
Outperform
$146.10B23.9530.53%3.48%1.99%-10.59%
CHCHD
70
Outperform
$23.79B41.4513.35%1.22%2.18%-26.08%
KMKMB
68
Neutral
$42.32B17.38229.84%3.95%-3.12%34.80%
68
Neutral
$42.24B40.1210.22%3.73%-1.18%-29.18%
CLCL
66
Neutral
$70.38B24.59977.07%2.40%0.98%12.12%
PGPG
65
Neutral
$363.64B24.6330.29%2.73%-0.16%2.74%
65
Neutral
$27.01B15.34-4.26%3.22%1.00%3.39%
* Consumer Defensive Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
KVUE
Kenvue, Inc.
22.00
4.43
25.21%
CHD
Church & Dwight
96.60
-2.90
-2.91%
CL
Colgate-Palmolive
86.84
-8.96
-9.35%
KMB
Kimberly Clark
127.53
-11.60
-8.34%
PG
Procter & Gamble
155.10
-9.00
-5.48%
UL
Unilever
59.70
3.38
6.00%

Kenvue, Inc. Corporate Events

Executive/Board ChangesBusiness Operations and Strategy
Kenvue Announces CEO Transition and Strategic Review
Neutral
Jul 14, 2025

On July 14, 2025, Kenvue announced a significant leadership change with the departure of CEO Thibaut Mongon and the appointment of Kirk L. Perry as interim CEO. This transition is part of a broader strategy to unlock shareholder value and enhance company performance. The Board is conducting a comprehensive review of strategic alternatives to optimize Kenvue’s brand portfolio and improve operational execution. The strategic review is advised by Centerview Partners and McKinsey & Company, aiming to accelerate growth and value creation for shareholders.

The most recent analyst rating on (KVUE) stock is a Hold with a $23.50 price target. To see the full list of analyst forecasts on Kenvue, Inc. stock, see the KVUE Stock Forecast page.

Executive/Board Changes
Kenvue Announces Leadership Change in Asia Pacific
Neutral
Jun 24, 2025

Kenvue Inc. announced a leadership transition in its Asia Pacific division, with Ellie Bing Xie stepping down as Group President on July 14, 2025, and Anindya Dasgupta taking over the role. Ms. Xie will remain with the company until August 8, 2025, to facilitate a smooth transition and will receive severance benefits as per the company’s plan. Mr. Dasgupta, with nearly 30 years of experience in the global consumer products industry, is expected to leverage his extensive expertise to drive growth in the Asia Pacific region, which generated approximately $3 billion in net sales in fiscal year 2024.

The most recent analyst rating on (KVUE) stock is a Hold with a $21.00 price target. To see the full list of analyst forecasts on Kenvue, Inc. stock, see the KVUE Stock Forecast page.

Executive/Board ChangesShareholder Meetings
Kenvue Inc. Shareholders Approve Key Proposals at 2025 Meeting
Neutral
May 27, 2025

Kenvue Inc. held its 2025 Annual Meeting of Shareholders on May 22, 2025, where shareholders voted on several key proposals. All 13 director nominees were elected to the Board of Directors, the compensation of the company’s named executive officers was approved on a non-binding advisory basis, and PricewaterhouseCoopers LLP was ratified as the independent registered public accounting firm for 2025.

The most recent analyst rating on (KVUE) stock is a Sell with a $18.00 price target. To see the full list of analyst forecasts on Kenvue, Inc. stock, see the KVUE Stock Forecast page.

Private Placements and FinancingBusiness Operations and Strategy
Kenvue Inc. Completes $750 Million Senior Notes Offering
Neutral
May 22, 2025

On May 22, 2025, Kenvue Inc. completed a public offering of $750 million in 4.850% Senior Notes due 2032, with the proceeds intended for general corporate purposes. The issuance, governed by an indenture with Deutsche Bank Trust Company Americas, includes limitations on certain company transactions and allows for early redemption, impacting Kenvue’s financial strategy and stakeholder interests.

The most recent analyst rating on (KVUE) stock is a Sell with a $18.00 price target. To see the full list of analyst forecasts on Kenvue, Inc. stock, see the KVUE Stock Forecast page.

Executive/Board ChangesFinancial Disclosures
Kenvue Appoints Amit Banati as New CFO
Negative
May 8, 2025

On May 8, 2025, Kenvue Inc. announced the appointment of Amit Banati as the new Chief Financial Officer, effective May 12, 2025, succeeding Paul Ruh who will transition to a strategic advisor role. The company also reported a 3.9% decrease in net sales for the first quarter of 2025 compared to the previous year, with plans to mitigate the impact of tariffs and foreign exchange rates on its financial outlook for the year.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 19, 2025